{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T23:37:01Z","timestamp":1777937821422,"version":"3.51.4"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T00:00:00Z","timestamp":1670284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T00:00:00Z","timestamp":1670284800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s10096-022-04537-x","type":"journal-article","created":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T13:11:28Z","timestamp":1670505088000},"page":"161-168","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["TIVAP-related infection due to Gram-negative aerobic bacilli: should TIVAP stay or should it go?"],"prefix":"10.1007","volume":"42","author":[{"given":"Simon","family":"Rolland","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Najiby","family":"Kassis-Chikhani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edouard","family":"Auclin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel","family":"Bensaid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Laure","family":"Bidaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Paule","family":"Gerlinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Damien","family":"Blez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Luc","family":"Mainardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7164-831X","authenticated-orcid":false,"given":"David","family":"Lebeaux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Dubert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,12,6]]},"reference":[{"issue":"19","key":"4537_CR1","doi-asserted-by":"publisher","first-page":"2538","DOI":"10.1001\/jama.1984.03340430036025","volume":"251","author":"JW Gyves","year":"1984","unstructured":"Gyves JW, Ensminger WD, Niederhuber JE, Dent T, Walker S, Gilbertson S et al (1984) A totally implanted injection port system for blood sampling and chemotherapy administration. JAMA 251(19):2538\u20132541. https:\/\/doi.org\/10.1001\/jama.1984.03340430036025","journal-title":"JAMA"},{"issue":"4","key":"4537_CR2","first-page":"706","volume":"92","author":"JE Niederhuber","year":"1982","unstructured":"Niederhuber JE, Ensminger W, Gyves JW, Liepman M, Doan K, Cozzi E (1982) Totally implanted venous and arterial access system to replace external catheters in cancer treatment. Surgery 92(4):706\u2013712","journal-title":"Surgery"},{"key":"4537_CR3","unstructured":"Groupe interdisciplinaire Francophone Acc\u00e8s Vasculaires (2021) Formation pour la bonne utilisation des CCI. https:\/\/www.gifav.org\/wp-content\/uploads\/2021\/06\/Formation-pour-la-bonne-utilisation-des.pdf. [Accessed 15 Mar 2022]"},{"issue":"2","key":"4537_CR4","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/S1473-3099(13)70266-4","volume":"14","author":"D Lebeaux","year":"2014","unstructured":"Lebeaux D, Fern\u00e1ndez-Hidalgo N, Chauhan A, Lee S, Ghigo J-M, Almirante B et al (2014) Management of infections related to totally implantable venous-access ports: challenges and perspectives. Lancet Infect Dis 14(2):146\u2013159. https:\/\/doi.org\/10.1016\/S1473-3099(13)70266-4","journal-title":"Lancet Infect Dis"},{"issue":"11","key":"4537_CR5","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/s1470-2045(02)00905-1","volume":"3","author":"S Kurul","year":"2002","unstructured":"Kurul S, Saip P, Aydin T (2002) Totally implantable venous-access ports: local problems and extravasation injury. Lancet Oncol 3(11):684\u2013692. https:\/\/doi.org\/10.1016\/s1470-2045(02)00905-1","journal-title":"Lancet Oncol"},{"issue":"12","key":"4537_CR6","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.revmed.2010.06.014","volume":"31","author":"D Lebeaux","year":"2010","unstructured":"Lebeaux D, Zarrouk V, Leflon-Guibout V, Lefort A, Fantin B (2010) Totally implanted access port-related infections: features and management. Rev Med Interne 31(12):819\u2013827. https:\/\/doi.org\/10.1016\/j.revmed.2010.06.014","journal-title":"Rev Med Interne"},{"key":"4537_CR7","doi-asserted-by":"publisher","unstructured":"Barbetakis N, Asteriou C, Kleontas A, Tsilikas C (2011) Totally implantable central venous access ports. Analysis of 700 cases. J Surg Oncol 104(6):654\u20136. https:\/\/doi.org\/10.1002\/jso.21990","DOI":"10.1002\/jso.21990"},{"issue":"1","key":"4537_CR8","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.medmal.2015.12.006","volume":"46","author":"M Vidal","year":"2016","unstructured":"Vidal M, Genillon JP, Forestier E, Trouiller S, Pereira B, Mrozek N et al (2016) Outcome of totally implantable venous-access port-related infections. Med Mal Infect 46(1):32\u201338. https:\/\/doi.org\/10.1016\/j.medmal.2015.12.006","journal-title":"Med Mal Infect"},{"issue":"6","key":"4537_CR9","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1097\/MD.0b013e318275ffe1","volume":"91","author":"D Lebeaux","year":"2012","unstructured":"Lebeaux D, Larroque B, Gellen-Dautremer J, Leflon-Guibout V, Dreyer C, Bialek S et al (2012) Clinical outcome after a totally implantable venous access port-related infection in cancer patients: a prospective study and review of the literature. Medicine (Baltimore) 91(6):309\u2013318. https:\/\/doi.org\/10.1097\/MD.0b013e318275ffe1","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"4537_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1086\/599376","volume":"49","author":"LA Mermel","year":"2009","unstructured":"Mermel LA, Allon M, Bouza E, Craven DE, Flynn P, O\u2019Grady NP et al (2009) Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 49(1):1\u201345. https:\/\/doi.org\/10.1086\/599376","journal-title":"Clin Infect Dis"},{"issue":"1","key":"4537_CR11","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1093\/jac\/dkh488","volume":"55","author":"BJ Rijnders","year":"2005","unstructured":"Rijnders BJ, Van Wijngaerden E, Vandecasteele SJ, Stas M, Peetermans WE (2005) Treatment of long-term intravascular catheter-related bacteraemia with antibiotic lock: randomized, placebo-controlled trial. J Antimicrob Chemother 55(1):90\u201394. https:\/\/doi.org\/10.1093\/jac\/dkh488","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"4537_CR12","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.idnow.2021.02.004","volume":"51","author":"Members of the Sous les Verrous Study Group","year":"2021","unstructured":"Members of the Sous les Verrous Study Group (2021) Antibiotic lock therapy for the conservative treatment of long-term intravenous catheter-related infections in adults and children: when and how to proceed? Guidelines for clinical practice 2020. Infect Dis Now 51(3):236\u2013246. https:\/\/doi.org\/10.1016\/j.idnow.2021.02.004","journal-title":"Infect Dis Now"},{"issue":"1","key":"4537_CR13","doi-asserted-by":"publisher","DOI":"10.1111\/tid.13017","volume":"21","author":"S Zanwar","year":"2019","unstructured":"Zanwar S, Jain P, Gokarn A, Devadas SK, Punatar S, Khurana S et al (2019) Antibiotic lock therapy for salvage of tunneled central venous catheters with catheter colonization and catheter-related bloodstream infection. Transpl Infect Dis 21(1):e13017. https:\/\/doi.org\/10.1111\/tid.13017","journal-title":"Transpl Infect Dis"},{"issue":"9","key":"4537_CR14","doi-asserted-by":"publisher","first-page":"e129","DOI":"10.1093\/cid\/cir551","volume":"53","author":"G Funalleras","year":"2011","unstructured":"Funalleras G, Fern\u00e1ndez-Hidalgo N, Borrego A, Almirante B, Planes AM, Rodr\u00edguez D et al (2011) Effectiveness of antibiotic-lock therapy for long-term catheter-related bacteremia due to Gram-negative bacilli: a prospective observational study. Clin Infect Dis Off Publ Infect Dis Soc Am 53(9):e129-132. https:\/\/doi.org\/10.1093\/cid\/cir551","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"issue":"9","key":"4537_CR15","doi-asserted-by":"publisher","first-page":"e00569","DOI":"10.1128\/AAC.00569-18","volume":"62","author":"MP Freire","year":"2018","unstructured":"Freire MP, Pierrotti LC, Zerati AE, Benites L, da Motta-Leal Filho JM, Ibrahim KY et al (2018) Role of lock therapy for long-term catheter-related infections by multidrug-resistant bacteria. Antimicrob Agents Chemother 62(9):e00569-e618. https:\/\/doi.org\/10.1128\/AAC.00569-18","journal-title":"Antimicrob Agents Chemother"},{"key":"4537_CR16","unstructured":"Sant\u00e9 Publique France (2019) Surveillance des infections associ\u00e9es aux dispositifs invasifs\u00a0: r\u00e9sultats de la surveillance men\u00e9e en. https:\/\/www.santepubliquefrance.fr\/import\/surveillance-des-infections-associees-aux-dispositifs-invasifs.-mission-nationale-spiadi.-resultats-de-la-surveillance-menee-en-2019; 2021. [Accessed 23 Sept 2021]"},{"key":"4537_CR17","unstructured":"D\u00e9termination de la sensibilit\u00e9 aux antibiotiques (2021) In : CASFM \/ EUCAST : Soci\u00e9t\u00e9 Fran\u00e7aise de Micrbiologie Ed. 7\u201327. https:\/\/www.sfm-microbiologie.org\/wp-content\/uploads\/2021\/04\/CASFM2021__V1.0.AVRIL_2021.pdf. [Accessed 15 Mar 2022]"},{"issue":"6","key":"4537_CR18","doi-asserted-by":"publisher","first-page":"451","DOI":"10.7326\/0003-4819-142-6-200503150-00011","volume":"142","author":"N Safdar","year":"2005","unstructured":"Safdar N, Fine JP, Maki DG (2005) Meta-analysis: methods for diagnosing intravascular device-related bloodstream infection. Ann Intern Med 142(6):451\u2013466. https:\/\/doi.org\/10.7326\/0003-4819-142-6-200503150-00011","journal-title":"Ann Intern Med"},{"issue":"8","key":"4537_CR19","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2016.0287","volume":"315","author":"M Singer","year":"2016","unstructured":"Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M et al (2016) The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 315(8):801\u2013810. https:\/\/doi.org\/10.1001\/jama.2016.0287","journal-title":"JAMA"},{"issue":"6","key":"4537_CR20","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1111\/apm.13033","volume":"128","author":"B Alonso","year":"2020","unstructured":"Alonso B, Fern\u00e1ndez-Cruz A, D\u00edaz M, S\u00e1nchez-Carrillo C, Mart\u00edn-Rabad\u00e1n P, Bouza E et al (2020) Can vancomycin lock therapy extend the retention time of infected long-term catheters? APMIS Acta Pathol Microbiol Immunol Scand 128(6):433\u2013439","journal-title":"APMIS Acta Pathol Microbiol Immunol Scand"}],"container-title":["European Journal of Clinical Microbiology & Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-022-04537-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10096-022-04537-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-022-04537-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T12:34:46Z","timestamp":1673526886000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10096-022-04537-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,6]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["4537"],"URL":"https:\/\/doi.org\/10.1007\/s10096-022-04537-x","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,6]]},"assertion":[{"value":"23 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Financial interests: authors SR, NK, EC, SB, ALB, MPG, DB, DL, and MD declare that they have no financial interests. JLM has received consulting fees from Bioaster as member of scientific committee and a speaking fee from Merck Sharp and Dome. Non-financial interests: authors SR, NK, EC, SB, ALB, MPG, DB, DL, and MD declare that they have no non-financial interests. JLM is an unpaid member of \u201cAssociation de chimioth\u00e9rapie anti-infectieuse\u201d and of scientific committee \u201cVaincre la mucoviscidose\u201d and has patents planned, issued, or pending (John Hopkins University, reference #C10895: Molecular Target of Mycobacterium Tuberculosis for Development of Drug and Vaccine; IDF-INNOV: New antibiotics targeting Mycobacteria. EP17306902.2. (22\/12\/2017); IDF-INNOV:New \u03b2-lactamase inhibitors targeting Gram n\u00e9gative bacteria. EP17020591.8 (22\/12\/2017) with no compensation received).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}